- Home
- FIVN vs ATAI Comparison
FIVN vs ATAI Comparison
Compare FIVN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVN | ATAI |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FIVN | ATAI |
|---|---|---|
| Price | $20.87 | $4.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $26.06 | $15.88 |
| AVG Volume (30 Days) | 3.4M | ★ 6.9M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,149,088,000.00 | $4,089,000.00 |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $99.24 | ★ N/A |
| Revenue Growth | 10.28 | ★ 1227.60 |
| 52 Week Low | $13.29 | $1.66 |
| 52 Week High | $30.35 | $6.73 |
Technical Indicators
Market Signals| Indicator | FIVN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 60.82 | 50.96 |
| Support Level | $20.49 | $3.30 |
| Resistance Level | $22.08 | $4.54 |
| Average True Range (ATR) | 1.47 | 0.26 |
| MACD | 0.30 | -0.05 |
| Stochastic Oscillator | 57.14 | 23.23 |
Price Performance
Historical ComparisonAbout FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.